NCT05984979Recruiting
The Daytime Circadian Rhythm in Exhaled Volatile Organic Compounds in People Living Without and Diabetes
The Daytime Circadian Rhythm in Exhaled Volatile Organic Compounds in People Living Without and With Type 1 and 2 Diabetes: an Exploratory Study
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. The study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type 2 diabetes. A total of 60 people will be recruited for the study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 24 Jul 2023
- Start date
- 7 Aug 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University of Bern
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT05984979
What you commit to
- Study type: Observational
- Planned participants: 60
- From 7 Aug 2023 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibiotic treatment in the previous 4 months
Other illness
- Any chronical lung and intestinal disease diagnosis (such as intestinal bowel disease (IBD); asthma; COPD (chronic obstructive pulmonary disease); lung cancer, …)
- Coeliac disease
- Any acute disease diagnosis (such as viral or bacterial infection)
Other
- Pregnancy or breastfeeding
- Smoking (last cigarette less than 6 months ago)
- Lactose and fructose intolerance
- Drinking habit of more than four units of alcohol per day
- Current inhaled medicines treatments
Who the study is looking for
- Subgroup 1:
- Age 18 or older
- HbA1c below 6.5%
- Written informed consent
- Subgroup 2:
- Age 18 or older
- T1D (Type 1 diabetes) with MDI (multiple daily injection) or CSII (Continuous subcutaneous insulin infusion therapy) therapy \>1 year
- Written informed consent
- Subgroup 3
- Age 18 or older
- T2D (Type 2 diabetes) with oral antidiabetic medication or insulin therapy
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.